Paeds SAQs · fetal-neonatal-and-perinatal
Fetal assessment, prenatal screening and counselling — formative SAQs
Two formative SAQs on antenatal fetal assessment: a no-call cell-free DNA result with counselling and diagnostic choice, and an abnormal growth scan with Doppler interpretation and delivery planning.
On this page & tools
Target exams
RACP General PaediatricsRACP DWEMRCPCH TheoryABP General Pediatrics
Prompt
Fetal assessment, prenatal screening and counselling
SAQ 1 — No-call cell-free DNA result in a higher-risk pregnancy (20 marks, ~15 minutes)
A 37-year-old woman at 11 weeks gestation, body mass index 34, has a cell-free DNA screen that reports a no-call result due to low fetal fraction. She asks whether that means the baby is fine and no further testing is needed. She lives two hours from the nearest diagnostic service and has intermittent phone reception. [1] [16]
Questions
- Define screening versus diagnostic testing and explain why this distinction matters now. (3 marks) [1]
- Explain why a no-call cell-free DNA result is not equivalent to a low-risk result. (4 marks) [1] [16]
- Outline the management options for a no-call result and the factors that guide the choice between repeat screen and diagnostic testing. (5 marks) [1] [11]
- Give four elements of non-directive counselling you would use with this woman at this visit. (4 marks) [6] [18]
- Describe four system actions that ensure she is not lost to follow-up given rural geography and access barriers. (4 marks) [18]
Model answer anchors
- Screening estimates a probability of a condition; diagnostic testing confirms or excludes it. A no-call screen is neither, so the distinction determines whether to repeat, diagnose or surveil rather than reassure. [1]
- A no-call reflects low fetal fraction, which is itself associated with raised maternal body mass index, early sampling, aneuploidy and fetal growth restriction; the no-call is therefore an informative signal carrying its own risk, not a low-risk result. [1] [16]
- Options are repeat cell-free DNA, diagnostic testing (chorionic villus sampling or amniocentesis by gestation), and detailed ultrasound with surveillance. Higher pre-test probability favours diagnostic testing over simple repeat screen; quoted procedure-related risk should be contemporary. [1] [11] [12]
- A no-call is not a normal result; what the next options are and their risks; that the choice is hers with support; clear written information; teach-back; named contact for questions. [6] [18]
- Book before discharge; dual contact details and a backup number; interpreter if needed; transport and leave-from-work support; active chase list; written and verbal plan with a named owner. [18]
Continue reading
Paediatrics Fellowship Pro
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References9Show ledgerHide ledger
- [1]Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. The New England journal of medicine, 2015.PMID 25830321
- [6]Prabhu M, Kuller JA, Biggio JR SMFM Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester. American journal of obstetrics and gynecology, 2021.PMID 34171388
- [8]Lees CC, Romero R, Stampalija T, et al. Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. American journal of obstetrics and gynecology, 2022.PMID 35026129
- [9]American College of Obstetricians and Gynecologists. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstetrics and gynecology, 2021.PMID 33481528
- [11]Salomon LJ, Sotiriadis A, Wulff CB, et al. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. Ultrasound in obstetrics & gynecology, 2019.PMID 31124209
- [12]Beta J, Zhang W, Geris S, et al. Procedure-related risk of miscarriage following chorionic villus sampling and amniocentesis. Ultrasound in obstetrics & gynecology, 2019.PMID 30977213
- [13]McGoldrick E, Stewart F, Parker R, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. The Cochrane database of systematic reviews, 2020.PMID 33368142
- [16]Society for Maternal-Fetal Medicine Publications Committee. SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. American journal of obstetrics and gynecology, 2015.PMID 26458766
- [18]Benachi A, Sarnacki S. Prenatal counselling and the role of the paediatric surgeon. Seminars in pediatric surgery, 2014.PMID 25459006